ArticlePloS one2017
Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- A systematic review of biomarkers to detect active tuberculosis.Nature microbiology · 2019Pooled it
- Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.PloS one · 2021Trial
- Machine learning approaches for tuberculosis prevalence and risk factor association among high-risk groups in Kigali health facilities.Research square · 2026Article
- Blinded trial of multiplex serodiagnostic test in India for diverse forms of active tuberculosis.Microbiology spectrum · 2026Article
- Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis.Biology direct · 2024Article
- Antibodies as key mediators of protection againstFrontiers in immunology · 2024Review
- Integrating pathogen- and host-derived blood biomarkers for enhanced tuberculosis diagnosis: a comprehensive review.Frontiers in immunology · 2024Review
- MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection.Pathogens (Basel, Switzerland) · 2023Article
- Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023Review
- The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Towards Accurate Point-of-Care Tests for Tuberculosis in Children.Pathogens (Basel, Switzerland) · 2022Review
- High Immunogenicity of a T-Cell Epitope-Rich Recombinant Protein Rv1566c-444 FromFrontiers in immunology · 2022Article
- multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection.medRxiv : the preprint server for health sciences · 2021Article
- Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis.Nature communications · 2021Article
- Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis.Frontiers in medicine · 2021Review
- Evaluation of multi-antigen serological screening for active tuberculosis among people living with HIV.PloS one · 2020Article
- Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.Frontiers in immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundImproved systematic screening of high-risk groups is a key component of the tuberculosis (TB) elimination strategy endorsed by the World Health Organization (WHO). We used a multiplex microbead immunoassay to measure antibody responses to 28 M. tuberculosis (M.tb) antigens, and assessed whether combinations of antibody responses achieve accuracy thresholds required for a TB screening test.
methodsA random selection of plasma samples obtained from consecutive HIV-negative adults who were admitted to Mulago Hospital in Kampala, Uganda with cough ≥2 weeks' but <6 months' duration were analyzed for serological response to 28 M.tb antigens using an in-house multiplex microbead immunoassay. We compared the median difference of the antibody response to each antigen between patients with and without culture-confirmed TB, ranked each antigen according to variable importance (VIM), and assessed the sensitivity and specificity of combinations of antibody responses using an advanced classification algorithm, SuperLearner.
resultsAmong the 237 patients included in the analysis, 119 (50%) were female, median age was 32 years (IQR 25, 46), and 113 (48%) had TB. Median antibody levels to eight antigens were significantly different between patients with and without TB. A panel including eight of the top ranked antigens had a sensitivity of 90.6% (95% CI 89.4, 93.8) and a specificity of 88.6% (95% CI 78.2, 97.6) (Ag85B, Ag85A, Ag85C, Rv0934-P38, Rv3881, BfrB, Rv3873, and Rv2878c). With sensitivity constrained to be >90%, specificity remained close to 70% with as few as 3 antigens included in the panels.
conclusionsMeasuring antibody responses to combinations of antigens could facilitate TB screening and should be further evaluated in populations being targeted for systematic screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.